Latest Baseimmune News & Updates

Baseimmune expands into fibrosis targeting IPF

They apply their computational protein design platform for multi-pathway immunotherapies. They announce a new Scientific Advisory Board of fibrosis experts.

Baseimmune hires Scientist – Protein Expression and Purification in London

The vacancy seeks protein expression and purification expertise in the London area, encouraging qualified candidates to apply and colleagues to share.

Baseimmune announces leadership updates and strategic focus

Joshua Blight is appointed Chief Scientific Officer, guiding scientific strategy and the antigen-design platform. Kevin Walton is appointed Chief Executive Officer, leading expansion into chronic diseases and multi-pathway biology.

Baseimmune announces Ariane steps down as CSO

Since 2019, she helped establish a robust immunotherapy platform and supported multiple funding rounds.

Baseimmune Announces Strategic Expansion into Fibrosis with Lead Program Targeting Idiopathic Pulmonary Fibrosis (IPF)

The complex and redundant biology underlying fibrosis is widely believed to contribute to the limited effectiveness of single-target approaches. "Fibrosis is a biologically complex, organ-specific...

Baseimmune Raises $11.3M in Series A funding to Develop Better Vaccines ...

– New investors MSD Global Health Innovation Fund and IQ Capital co-led Series A with existing investors participating – AI-based design algorithm shortens the time...

London Bioscience Innovation Centre Welcomes Baseimmune Ltd to its New Fully Fitted Grow-On Lab Space within The Apex Building, Tribeca | UKSPA

The novel vaccine developer will occupy 3,350 sq ft of lab and office space in LBIC's new, fully fitted, grow-on space within the Apex building,...

Baseimmune launches for AI-based vaccine development